Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Find People
Find Everything
About This Site
Edit My Profile
Export RDF
Login to Profiles

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Gangadhar TC, Clark JI, Karrison T, Gajewski TF. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Benzodioxoles
Female
Humans
Interleukin-2
Male
Melanoma
Middle Aged
Neoplasm Metastasis
Protein Kinase Inhibitors
Quinazolines
src-Family Kinases
T-Lymphocytes
Treatment Outcome

authors with profiles

Theodore Karrison
Thomas F. Gajewski